Clinical Trial

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-08-25; most recent amendment 2026-02-25.
Status change: Active, Not Recruiting → Completed 2026-01-26
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-09-18
Trial Details
NCT Number NCT07142642
Lead Sponsor Amgen
Conditions Healthy Volunteers
Enrollment 20 participants
Start Date 2025-08-26
Primary Completion 2025-11-22 (estimated)
Study Completion 2026-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-27